Key Takeaways
- Johnson & Johnson’s fourth quarter sales met estimates, while net income fell short.
- After adjusting for one-time costs like acquisitions, the drug and medical device maker’s adjusted profits beat estimates.
- The company’s projections for sales during the 2025 fiscal year also came in short of current analyst estimates.
Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company’s sales projections for the coming fiscal year fell short.
The drug and medical device maker reported $22.52 billion in revenue, in line with analyst estimates compiled by Visible Alpha. The company’s profits fell short, however, at $3.43 billion, or $1.41 per share, while analysts had expected $4.41 billion and $1.79 per share.
After accounting for one-time costs like asset amortization and acquisition-related costs, Johnson & Johnson’s adjusted net income came in at $4.94 billion, just above the $4.88 billion analyst consensus.
The company also outlined its projections for fiscal 2025, as it expects revenue between $89.2 billion to $90 billion, along with an adjusted earnings per share range of $10.50 to $10.70. Analysts currently project a larger revenue figure at $91.18 billion, and adjusted EPS of $10.54, per Visible Alpha estimates.
Sales in the company’s two divisions of pharmaceuticals and medical technology each rose from the same time last year by 4.4% and 6.7%, respectively.
Shares of Johnson & Johnson were down more than 1% Wednesday morning.
:max_bytes(150000):strip_icc()/GettyImages-1741330345-4afa32dc044348cbbc951ae96330ce15.jpg?w=1200&resize=1200,0&ssl=1&description=J%26J+Tops+Q4+Adjusted+Earnings+Estimates%2C+But+2025+Sales+Outlook+Falls+Short){kind=link}